SEATTLE & TOKYO--(BUSINESS WIRE)--Acucela Inc. and Otsuka Pharmaceutical Co., Ltd. today announced that they have entered into a definitive agreement on September 24, 2010 to co-develop and co-promote OPA-6566, an adenosine A2a receptor agonist discovered and currently under development by Otsuka for the treatment of glaucoma, in the United States.
